KDELC2 inhibitors comprise a group of chemical compounds that interfere with the function of the protein by disrupting specific pathways and processes in glycosylation and glycoprotein trafficking.
Swainsonine and Kifunensine target the mannosidase enzymes, which are essential for the trimming of mannose residues during N-glycan maturation, a process in which KDELC2 is implicated. The impairment of glycan maturation due to these inhibitors can lead to the functional inhibition of KDELC2. Similarly, Benzyl-α-GalNAc and Castanospermine inhibit the O-glycosylation and glucosidase activities, respectively, causing a build-up of misprocessed glycoproteins and disrupting the glycan structures that KDELC2 typically handles.
SEE ALSO...
Items 11 to 11 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that inhibits calcineurin, affecting multiple signaling pathways. Although not directly related to glycosylation, its broad effects can indirectly inhibit KDELC2 by altering cellular processes that depend on proper glycosylation. | ||||||